CANNABIS INVESTMENTS
Tu Diep
Chief Development Officer,
Skye Bioscience, Inc
Follow
About Tu
Tu Diep brings more than 15 years of scientific and clinical research experience to Skye Bioscience. Prior to joining Skye, he was at Protox Therapeutics Inc., (now Sophiris Bio Inc.), a company developing highly targeted, minimally invasive treatment for benign prostatic hyperplasia and prostate cancer. While at Protox, Mr. Diep held several positions with increasing responsibility where he gained extensive experience in preclinical research and development, clinical protocol development and design, clinical operations, and biologics manufacturing. Prior to leaving Protox, Mr. Diep was integrally involved in solidifying a $75 million regional partnership with a Japanese pharmaceutical company, as well as, securing a $35 million investment from the private equity firm, Warburg Pincus.
Tu's Videos
During the last few years, the landscape of the cannabis industry has changed, and the United States has become the most important market for the industry. Today, you will learn about the global cannabis opportunity and certain verticals of the US market that are flying under the radar. With a diverse panel of industry executives and experts, you will be able learn how they are positioned to capitalize on it.
Tu Diep
CANNABIS INVESTMENTS
53:55